Ironwood Pharmaceuticals has initiated an NDA for apraglutide, targeting SBS patients dependent on parenteral support. The STARS trial demonstrated significant reductions in parenteral support volume ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results